What's new

Helsinki Biobank and Fimmic Introduce a Unique One Access Service for Biomedical Research

Tissue sample collections and digital services with deep learning -based image analysis solutions now available as a combined service

Helsinki Biobank and medical AI software company Fimmic announce a collaboration by presenting a unique one access service concept. The new service combines Helsinki Biobank´s large collection of pathology samples and world-class digital services with state-of-the art deep learning AI -based image analysis solutions from Fimmic.

Life Science Mentors – Mentoring Service for Finnish Life Science Actors

Finnish industry organisations in the Life Science field have collaboratively created an internet based mentoring service for start-up companies, fledgling entrepreneurs and researchers interested in commercialising their inventions. The purpose of the service is to share the knowledge of experienced people with beginners and support their business development. The service is offered free of charge.

Faron Pharmaceuticals Admission to AIM and first day of dealings £10 million fundraise to progress Phase III clinical trial

Faron Pharmaceuticals Oy ("Faron”), the clinical stage biopharmaceutical company, is pleased to announce the commencement of dealings in its Ordinary Shares on the AIM market of the London Stock Exchange with effect from 8.00 a.m. today under the ticker FARN and the ISIN number FI4000153309. This follows a successful placing and subscription for 3,846,154 new Ordinary Shares, raising £10.0 million at a price of 260p per ordinary share (the “Fundraising”).

  1. Faron Enters Agreement with Selexis SA to Progress Development of Novel Cancer Immunotherapy Clevegen
  2. Fimmic closes investment round to digitalize cancer diagnostics
  3. Faron Pharmaceuticals Oy Intention to Float on AIM
  4. Innomedica to open new office in Switzerland
  5. FIT Biotech’s Initial Public Offering Completed Successfully
  6. BioFinland prize to Biovian Oy
  7. Forendo Pharma announces the US licensing of fispemifene to Apricus Biosciences targeting urological conditions in men
  8. Oncos Therapeutics Demonstrates Systemic, Tumor-specific Immune Response by Local Administration of its Lead Product ONCOS-102
  9. Promising new treatment for life threatening acute respiratory distress syndrome (ARDS)
  10. A Special Year for the Biotech Sector
  11. KU Leuven and FIT Biotech enter into a worldwide license and collaboration agreement for the development of novel immunotherapeutics
  12. Neste Jacobs and Roal Sign a Contract to Expand Enzyme Production Plant
  13. BioFinland 2013 prize to Glykos Finland Ltd
  14. Culminatum Innovation and Diaceutics Collaborate to Provide Expert Training to Leading Finnish Researchers on Commercializing Biomarkers for Personalized Medicine
  15. Innomedica and CMC Biologics into strategic agreement for Japan market
  16. The Future Generation of Bioscientists - Lost or Found?
  17. Culminatum works to develop an attractive innovation environment for biotechnology in the BSR
  18. New Horizons For the Bioindustry
  19. Faron reports positive headline data from FPCLI001 clinical study with FP- 1201 in acute lung injuries
  20. An Insider’s View: Report on the Finnish Life Sciences Industry
  21. Faron and Maruishi Sign Traumakine-program License Agreement
  22. Rentschler to manufacture Faron product Traumakine®
  23. Change of management in Novamass Ltd
  24. Fulfilling the Promises
  25. Innomedica Expands in UK – Dr Jim Phillips Joins the Team
  26. Finland is a Forerunner in Biomass Refining
  27. Biobanks—Opportunities Becoming Reality
  28. The Perceived Value-added of Venture Capital Investors: Evidence from Finnish biotechnology industry
  29. Coaching small biotech companies into success: The value-adding function of VC
  30. Promoting innovation by tax incentives—A review of strategies and their importance to biotech growth
  31. European Biotech industry figures show signs of chronic under-funding
  32. ETLA 2004 Survey on the Finnish Biotechnology Industry--Background and Descriptive Statistics
  33. State of the Biotechnology Industry
  34. Intellectual Capital and Anticipated Future Sales in Small and Medium-sized Biotechnology Companies
  35. Ownership and Financial Structure of Biotechnology SMEs: Evidence from Finland
  36. Findings of the ETLA Survey on Finnish Biotechnology Firms
  • You are here:  
  • Home
  • What's new